Platelet aggregation and antiplatelet agents in acute coronary syndromes

被引：4

作者：

Collet, JP ^{[1
]}

Choussat, M ^{[1
]}

Montalescot, G ^{[1
]}

机构：

[1] Hop La Pitie Salpetriere, Inst Cardiol, F-75013 Paris, France

来源：

M S-MEDECINE SCIENCES | 2004年 / 20卷 / 03期

关键词：

D O I：

10.1051/medsci/2004203291

中图分类号：

R-3 [医学研究方法]; R3 [基础医学];

学科分类号：

1001 ;

摘要：

Antiplatelet agents are the cornerstone therapy of acute coronary syndromes. In the setting of ST elevation myocardial infarction, antiplatelet therapy prevent the prothrombotic effect of reperfusion therapy including thrombolysis and primary percutaneous coronary intervention. In non ST-elevation acute coronary syndromes, antiplatelet therapy prevent s complete coronary thrombotic occlusion and therefore the occurrence of ST elevation myocardial infarction. Antiplatelet agent benefit is related to the patient's risk profile. It is well established that combined antiplatelet therapy is the most effective in high risk patients. Several important issues have to be faced including the identification of non responders, dose adjustment and the management of temporary interruption of antiplatelet agents in stable coronary artery disease patients.

引用

页码：291 / +

页数：8

共 27 条

[1] Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes:: a meta-analysis of all major randomised clinical trials [J].

Boersma, E ;

Harrington, RA ;

Moliterno, DJ ;

White, H ;

Théroux, P ;

Van de Werf, F ;

de Torbal, A ;

Armstrong, PW ;

Wallentin, LC ;

Wilcox, RG ;

Simes, J ;

Califf, RM ;

Topol, EJ ;

Simoons, ML .

LANCET, 2002, 359 (9302) :189-198

[2] ACC/AHA guideline update for the management of patients with unstable angina and non-ST-segment elevation myocardial infarction-2002: Summary article - A report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Committee on the Management of Patients With Unstable Angina) [J].

Braunwald, E ;

Antman, EM ;

Beasley, JW ;

Califf, RM ;

Cheitlin, MD ;

Hochman, JS ;

Jones, RH ;

Kereiakes, D ;

Kupersmith, J ;

Levin, TN ;

Pepine, CJ ;

Schaeffer, JW ;

Smith, EE ;

Steward, DE ;

Theroux, P ;

Gibbons, RJ ;

Alpert, JS ;

Faxon, DP ;

Fuster, V ;

Gregoratos, G ;

Hiratzka, LF ;

Jacobs, AK ;

Smith, SC .

CIRCULATION, 2002, 106 (14) :1893-1900

[3]

BRENER SJ, 1998, CIRCULATION, V98, P34

[4] USE OF A MONOCLONAL-ANTIBODY DIRECTED AGAINST THE PLATELET GLYCOPROTEIN IIB/IIIA RECEPTOR IN HIGH-RISK CORONARY ANGIOPLASTY [J].

CALIFF, RM ;

SHADOFF, N ;

VALETT, N ;

BATES, E ;

GALEANA, A ;

KNOPF, W ;

SHAFTEL, J ;

BENDER, MJ ;

AVERSANO, T ;

RAQUENO, J ;

GURBEL, P ;

COWFER, J ;

COHEN, M ;

CROSS, P ;

BITTL, J ;

EDDINGS, K ;

TAYLOR, M ;

DEROSA, K ;

HATTEL, L ;

COOPER, L ;

ESHELMAN, B ;

FINTEL, D ;

NIEMYSKI, P ;

KLEIN, L ;

KENNEDY, H ;

THORNTON, T ;

KEREIAKES, D ;

MARTIN, L ;

ANDERSON, L ;

HIGBY, N ;

ELLIS, S ;

BREZINA, K ;

GEORGE, B ;

CHAPEKIS, A ;

SMITH, D ;

ANWAR, A ;

GERBER, TL ;

PRITCHARD, GL ;

MYLER, R ;

SHAW, R ;

MURPHY, M ;

WARD, K ;

MADIGAN, NP ;

BLANKENSHIP, J ;

HALBERT, M ;

FLANAGAN, C ;

TANNENBAUM, M ;

POLICH, M ;

STEVENSON, C ;

TCHENG, J .

NEW ENGLAND JOURNAL OF MEDICINE, 1994, 330 (14) :956-961

[5] Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. [J].

Cannon, CP ;

Weintraub, WS ;

Demopoulos, LA ;

Vicari, R ;

Frey, MJ ;

Lakkis, N ;

Neumann, FJ ;

Robertson, DH ;

DeLucca, PT ;

DiBattiste, PM ;

Gibson, CM ;

Braunwald, E .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (25) :1879-1887

[6] Randomized double-blind safety study of enoxaparin versus unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes treated with tirofiban and aspirin:: The ACUTE II study [J].

Cohen, M ;

Théroux, P ;

Borzak, S ;

Frey, MJ ;

White, HD ;

Van Mieghem, W ;

Senatore, F ;

Lis, J ;

Mukherjee, R ;

Harris, K ;

Bigonzi, F .

AMERICAN HEART JOURNAL, 2002, 144 (03) :470-477

[7] Enoxaparin in unstable angina patients who would have been excluded from randomized pivotal trials [J].

Collet, JP ;

Montalescot, G ;

Fine, E ;

Golmard, JL ;

Dalby, M ;

Choussat, R ;

Ankri, A ;

Dumaine, R ;

Lesty, C ;

Vignolles, N ;

Thomas, D .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2003, 41 (01) :8-14

[8] Myocardial infarction after aspirin cessation in stable coronary artery disease patients [J].

Collet, JP ;

Himbert, D ;

Steg, PG .

INTERNATIONAL JOURNAL OF CARDIOLOGY, 2000, 76 (2-3) :257-258

[9] Eptifibatide provides additional platelet inhibition in non-ST-elevation myocardial infarction patients already treated with aspirin and clopidogrel - Results of the platelet activity extinction in non-Q-wave myocardial infarction with aspirin, clopidogrel, and eptifibatide (PEACE) study [J].

Dalby, M ;

Montalescot, G ;

Sollier, CBD ;

Vicaut, E ;

Soulat, T ;

Collet, JP ;

Choussat, R ;

Gallois, V ;

Drobinski, G ;

Drouet, L ;

Thomas, D .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 2004, 43 (02) :162-168

[10] IRREGULAR CORONARY LESION MORPHOLOGY AFTER THROMBOLYSIS PREDICTS EARLY CLINICAL INSTABILITY [J].

DAVIES, SW ;

MARCHANT, B ;

LYONS, JP ;

TIMMIS, AD ;

ROTHMAN, MT ;

LAYTON, CA ;

BALCON, R .

JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1991, 18 (03) :669-674

← 1 2 3 →